<unk>  is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) or relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.
Crizotinib
Icotinib
Nilotinib
Tepotinib
Afatinib
Imatinib
Ruxolitinib
Neratinib